FATE News and Press, Fate Therapeutics Inc. From 06/04/21

Fate Therapeutics (FATE) highlights positive interim Phase 1 data from its FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting held virtually June 4-8, 2021. As of the data cutoff date of March 11, 202...

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable FT516 Safety Profile Was Observed; No FT516-related Seri...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonable prices for biotech companies, according to Jefferies analyst Michael Yee."Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed from and 6 added to the universe now hol...

Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s Margaret Kaczor thinks the group of med-tech stocks are attractive buys on the pullback.Des...

This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for pot...

Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de...

Fate Therapeutics (FATE) announces promising interim early-stage data from the company’s off-the-shelf, iPSC-derived natural killer ((NK)) cell programs in relapsed / refractory acute myeloid leukemia ((AML)).The ongoing Phase 1 dose-escalation study of FT516 as monotherapy is currentl...

4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study Continued in Remission without Further Therapeutic Intervention at 6-month Foll...